

EXTENDED REPORT

MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behçet's disease and Vogt–Koyanagi–Harada syndrome

Qingyun Zhou,¹ Shengping Hou,¹ Liang Liang,¹ Xinyu Li,¹ Xiaoyu Tan,¹ Lin Wei,¹ Bo Lei,¹ Aize Kijlstra,² Peizeng Yang¹**Handling editor** Tore K Kvien

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2012-201627>).

¹Chongqing Key Laboratory of Ophthalmology, and Chongqing Eye Institute, The First Affiliated Hospital of Chongqing Medical University, Chongqing, P R China

²Department of Ophthalmology, Eye Research Institute Maastricht, University Hospital Maastricht, Maastricht, The Netherlands

Correspondence to

Dr Peizeng Yang, Chongqing Key Laboratory of Ophthalmology, and Chongqing Eye Institute, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China; peizengycmu@126.com

Received 3 March 2012

Revised 30 November 2012

Accepted 2 December 2012

Published Online First

25 December 2012

ABSTRACT

Aim MicroRNA-146a (miR-146a) is involved in certain immune-mediated diseases. Transcription factor Ets-1 strongly affects miR-146a promoter activity and directly regulates miR-146a expression. This study was performed to investigate the association of *miR-146a* and *Ets-1* gene polymorphisms with Behçet's disease (BD) and Vogt–Koyanagi–Harada (VKH) disease in a Chinese Han population.

Methods A total of 809 patients with BD, 613 patients with VKH and 1132 normal controls were genotyped for miR-146a/rs2910164, rs57095329 and rs6864584, Ets-1/rs1128334 and rs10893872 using a PCR restriction fragment length polymorphism assay. miR-146a expression was examined in peripheral blood mononuclear cells (PBMCs) by real-time PCR. Cytokine production by PBMCs was measured by ELISA.

Results A significantly decreased frequency of the homozygous rs2910164 CC genotype and C allele was observed in patients with BD compared with controls ($p^a=1.24\times 10^{-5}$, OR 0.61; $p^a=1.33\times 10^{-4}$, OR 0.75, respectively). MiR-146a expression in GG cases was 2.45-fold and 1.99-fold higher, respectively, than that in CC cases and GC cases. There was no association of the other four single nucleotide polymorphisms (SNPs) with BD. There was also no association of these five SNPs with its main clinical features. No associations were found with the five SNPs tested or with its clinical manifestations in VKH disease. Interleukin (IL)-17, tumour necrosis factor (TNF) α and IL-1 β production from rs2910164 CC cases was markedly lower than that in GG cases. No effect of genotype was observed on IL-6 and monocyte chemoattractant protein (MCP)-1 production and IL-8 expression was slightly higher in CC cases.

Conclusions Our study identified a strong association of rs2910164 of miR-146a with BD in a Chinese population and decreased expression of miR-146a and certain proinflammatory cytokines in individuals carrying the CC genotype.

INTRODUCTION

Behçet's disease (BD) is a chronic, multisystem inflammatory disease. It is more prevalent in the region that extends from China and Japan in the Far East to the Mediterranean sea.^{1 2} Vogt–Koyanagi–Harada (VKH) disease is an autoimmune disorder characterised by bilateral granulomatous panuveitis frequently associated with systemic involvement and frequently affects Asians and

Native Americans.^{3 4} Although the exact aetiology and pathogenesis of both diseases remain unclear, the role of genetic factors in their pathogenesis has long been recognised.^{5–7} Various studies have reported that human leukocyte antigen (HLA) genes, such as *HLA-B51*, and several non-HLA genes including *IL23R-IL12RB2* and *IL10* genes are associated with BD.^{8–10} *HLA-DR4* and *IL-17* polymorphisms have been found to be associated with VKH disease.^{11 12} These reports suggest that genetic factors may play a role in these two diseases.

Micro RNAs (miRNAs) have been recently recognised as an important regulator in immune homeostasis. Abnormalities in the miRNA-mediated regulation of immune-cell development and function have been linked to autoimmunity and inflammatory diseases.^{13 14} Tang *et al*¹⁵ demonstrated that miR-146a was a negative regulator of innate immunity in patients with systemic lupus erythematosus (SLE). Recent studies have demonstrated that single nucleotide polymorphisms (SNPs) located either in the pre-miRNAs or within miRNA binding sites are likely to affect the expression of the miRNA targets and, thus, may contribute to the susceptibility to diseases.^{16 17} V-Ets oncogene homologue 1 (*Ets-1*), the first member of the *Ets* oncogene family, has been identified in the avian erythroblastosis virus E26 and shown to contribute to tumour development and progression.¹⁸ Recently, Luo *et al*¹³ identified that *Ets-1* binds to the miR-146a promoter region and strongly affected miR-146a promoter activity in vitro. In vivo experiments have shown that the knockdown of *Ets-1* directly impaired the induction of miR-146a.¹³ It has recently also been shown that SNP rs1128334 and rs10893872 located in the 3'-untranslated region (3'-UTR) of *Ets-1* are on putative miRNA binding sites and are both associated with SLE in Asian populations.¹⁹ All these results suggested that *Ets-1* influences the expression and activity of miR-146a.

In view of the important role of miR-146a in the development of inflammation-related and autoimmune diseases and the potential modulatory effect of *Ets-1* on miR-146a expression, we examined whether polymorphisms of both genes were associated with BD and, if so, whether the variant affected gene expression and relevant cytokine production. VKH disease was chosen as a disease control mainly based on a similar prevalence in Chinese population and the similar clinical features, such as recurrent episodes and difficulty in the

To cite: Zhou Q, Hou S, Liang L, *et al*. *Ann Rheum Dis* 2014;**73**:170–176.

treatment although they are different in disease nature (BD, non-granulomatous inflammation; VKH disease, granulomatous inflammation).

MATERIALS AND METHODS

Study population

The study group comprised 809 consecutive patients with BD who were recruited from the First Affiliated Hospital of Chongqing Medical University (Chongqing, China) and the Zhongshan Ophthalmic Center of Sun Yat-sen University (Guangzhou, China) between October 2006 and October 2012. A total of 1132 unselected, consecutive control subjects were matched ethnically and geographically with the patients. Patients with VKH were used as disease controls. BD and VKH disease were strictly diagnosed based on the criteria of the [International Study Group for BD²⁰](#) and First International Workshop for VKH,²¹ respectively. If the diagnosis was in any doubt, the patients were excluded from the study. A Hardy–Weinberg equilibrium (HWE) calculation was performed to ensure a balance in genotype and allele distribution between patients and normal controls. A binary logistic regression analysis was applied to avoid the effect of gender on the association of the variants with BD. Direct sequencing was performed in 20% of the total samples randomly chosen in order to validate the method employed in this study. The study received the approval of the Local Ethics Research Committee and all the investigated subjects provided informed consent before collection of blood. The tenets of the Declaration of Helsinki were upheld during all procedures of this study.

DNA extraction and genotyping

Genomic DNA samples from patients with BD, patients with VKH and healthy controls were extracted by using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, California, USA). The target DNA sequence was amplified by the PCR using proper primers (see online supplementary table S1). PCR products were digested with 2 U of HSP92II (Promega, Madison, Wisconsin, USA), *MspI* (Fermentas, Shenzhen, China), *ApaI* (Fermentas, Shenzhen, China), *AflII* (Fermentas, Shenzhen, China) and TSP509I (Fermentas, Shenzhen, China) restriction enzymes in a 10 µl reaction volume overnight. HSP92II digested the introduced mismatch restriction sites of SNPs rs2910164 and rs1128334. *MspI* and *AflII* digested the introduced mismatch restriction sites of SNPs rs57095329 and rs17057381, respectively. *ApaI* and TSP509I digested the natural restriction sites of SNP rs6864584 and SNP rs10893872, respectively. The formed digestion products were separated on 4% agarose gels and stained with GoldView (SBS Genetech Beijing, China).

Cell isolation and culture

Peripheral blood mononuclear cells (PBMCs) were isolated from heparinised blood samples by Ficoll-Hypaque density-gradient centrifugation. Isolated PBMCs cells (2×10^6 cells per well) were seeded in 24-well plates and cultured in RPMI medium 1640 supplemented with 10% fetal calf serum (FCS, Greiner, Wemmel, Belgium), 100 U/ml penicillin, 100 µg/ml streptomycin. In order to detect interleukin (IL)-17 production, PBMCs were cultured with anti-CD3 antibody (5 µg/ml, eBioscience, San Diego, California, USA) and anti-CD28 antibody (1 µg/ml, eBioscience) for 3 days. For tumour necrosis factor (TNF)α, IL-1β, IL-8, IL-6 and monocyte chemoattractant protein (MCP)-1 detection, PBMCs were cultured with 100 ng/ml lipopolysaccharide (LPS, 100 ng/ml; Sigma, Missouri, USA) for 24 h.

Real-time PCR

Total RNA was extracted from PBMCs using TRIzol (Invitrogen, San Diego, California, USA), followed by reverse transcription using transcriptase kit (Applied Biosystems, ABI, Foster City, California, USA). The quantity of mature miR-146a was determined by TaqMan MicroRNA Assay kit (ABI) and normalised to snRNA U6. The assays were performed on a 7500 real-time instrument (ABI). Relative expression levels were calculated using the $2^{-\Delta\Delta C_t}$ method.

ELISA

The concentration of IL-17, TNFα, IL-1β, IL-8, IL-6 and MCP-1 in the supernatants of PBMCs were measured using the human DuoSet ELISA development kit (R&D Systems, Minneapolis, Minnesota, USA) according to the manufacturer's protocols.

Statistical analysis

For single SNP analysis, genotype and allele frequencies were compared between patients and controls by χ^2 test using SPSS V17.0 (SPSS, Inc., Chicago, Illinois, USA). The χ^2 test was also applied to analyse the HWE. A binary logistic regression analysis was used to assess the influence of gender on the association of five SNPs with BD. The non-parametric Mann–Whitney test was used to compare miR-146a expression and cytokine levels among three genotype groups. Two-tailed p values <0.05 were considered to be statistically significant.

RESULTS

Clinical features of patients with BD and patients with VKH

Detailed clinical findings of the enrolled BD and patients with VKH are presented in table 1. Age and gender distribution in

Table 1 Clinical characteristic, age and gender distribution in patients with BD and patients with VKH

Extraocular findings	Total	%
Patients with BD	809	
Mean age±SD	32.1±12.7	
Male	678	83.8
Female	131	16.2
Uveitis	809	100
Oral ulcer	809	100
Genital ulcer	325	40.2
Skin lesions	458	56.6
Arthritis	176	21.8
Positive pathergy test	198	24.5
Patients with VKH	613	
Mean age±SD	33.2±8.9	
Male	326	53.2
Female	287	46.8
Uveitis	613	100
Headache	309	50.4
Tinnitus	248	40.5
Vitiligo	170	27.7
Alopecia and poliosis	273	44.5
Controls	1132	
Mean age±SD	35.1±11.8	54.7
Male	619	45.3
Female	513	

BD, Behçet's disease; VKH, Vogt–Koyanagi–Harada.

Clinical and epidemiological research

patients with VKH, patients with BD and controls are also presented in table 1.

Allele and genotype frequencies of SNPs in patients and controls

A total of 5 SNPs were successfully genotyped in 809 patients with BD, 613 patients with VKH and 1132 normal controls. The sequencing details are shown in online supplementary figure S1. The distribution of genotype frequencies of the five SNPs did not deviate from HWE in the controls. Our results showed that there was a significant difference between patients with BD and normal controls concerning the frequency of rs2910164. The frequency of the CC genotype and C allele of rs2910164 in patients with BD was significantly lower than that in normal controls ($p=3.60\times 10^{-7}$, $p_c^a=1.24\times 10^{-5}$, OR 0.61; $p=1.44\times 10^{-5}$, $p_c^a=1.33\times 10^{-4}$, OR 0.75, respectively) (tables 2 and 3). The frequency of the rs2910164 CG genotype was significantly increased in patients with BD compared with controls ($p=1.89\times 10^{-4}$, $p_c^a=5.95\times 10^{-3}$, OR 1.42). There was no statistically significant difference concerning the genotype and allele of the other four SNPs between patients with BD and controls after gender correction. As BD involves various organs, we further performed a study on the association of these five SNPs with clinical findings of this disease including hypopyon, genital ulcers, skin lesions and arthritis. Our study failed to find any association of these disease parameters with the tested SNPs. The genotype and allele frequencies of rs2910164, rs57095329, rs6864584, rs1128334 and rs10893872 showed no difference between patients with VKH and normal controls (tables 2 and 3). There was also no association of these five SNPs with extraocular manifestations of VKH disease including headache, tinnitus, vitiligo, alopecia and poliosis.

The influence of rs2910164 on miR-146a expression

The aforementioned result identified a strong association of SNP rs2910164 with BD. We further evaluated the expression of miR-146a in PBMCs derived from 24 healthy individuals with a known SNP (rs2910164) status. Mature miR-146a level was measured by the TaqMan microRNA assay with available RNA samples. The mean expression of miR-146a in GG cases was 2.45-fold and 1.99-fold higher than that in CC ($p=0.009$) and GC cases ($p=0.018$), respectively (figure 1).

The influence of rs2910164 on cytokine production

A further experiment was performed to examine different genotypes of SNP rs2910164 on cytokines important to the development of BD such as IL-17, TNF α , IL-1 β , IL-8, IL-6 and MCP-1. The results showed that the IL-17 production by stimulated PBMCs from CC cases (603.57 ± 352.73 pg/ml) were lower than that in GC (1012.55 ± 716.65 pg/ml, $p=0.028$) and GG cases (1471.43 ± 734.31 pg/ml, $p<0.001$), respectively. TNF α production by stimulated PBMCs from CC cases (1454.41 ± 485.86 pg/ml) was lower than that in GC (1929.95 ± 676.12 pg/ml, $p=0.006$) and GG cases (2200.98 ± 758.27 pg/ml, $p<0.001$), respectively. A similar result was also present concerning the IL-1 β expression between GC and CC cases. IL-1 β production by stimulated PBMCs from CC cases (99.12 ± 69.20 pg/ml) was lower than that in GC cases (328.85 ± 309.53 pg/ml, $p<0.001$). There was no significant difference between GC and GG genotypes ($p=0.057$) and no significant association was observed concerning the IL-6 and MCP-1 production by stimulated PBMCs and the three different genotypes. However, the IL-8 expression in the supernatants of stimulated PBMCs from CC cases (28.73 ± 3.11 ng/ml) was higher as

Table 2 Frequencies of genotypes and alleles of micro RNA (miR)-146a and Ets-1 polymorphism in patients with BD and controls

SNP	Genotype allele	BD (N=809)	Controls (N=1132)	χ^2	p Value	p_c^a Value	OR (95% CI)
Rs2910164	GG	131 (0.162)	154 (0.136)	2.524	0.119	NS	1.23 (0.95 to 1.58)
	GC	440 (0.544)	518 (0.458)	14.26	1.89×10^{-4}	5.95×10^{-3}	1.42 (1.18 to 1.70)
	CC	238 (0.294)	460 (0.406)	25.78	3.60×10^{-7}	1.24×10^{-5}	0.61 (0.50 to 0.74)
	G	702 (0.434)	826 (0.365)	18.84	1.44×10^{-5}	1.33×10^{-4}	1.33 (1.17 to 1.52)
	C	916 (0.566)	1438 (0.635)	18.84	1.44×10^{-5}	1.33×10^{-4}	0.75 (0.66 to 0.85)
Rs57095329	AA	567 (0.701)	761 (0.672)	1.787	0.198	NS	1.14 (0.94 to 1.39)
	AG	224 (0.277)	342 (0.302)	1.454	0.244	NS	0.88 (0.73 to 1.08)
	GG	18 (0.022)	29 (0.026)	0.227	0.657	NS	0.87 (0.48 to 1.57)
	A	1358 (0.839)	1864 (0.823)	1.71	0.191	NS	1.12 (0.94 to 1.33)
	G	260 (0.161)	400 (0.177)	1.71	0.191	NS	0.89 (0.75 to 1.06)
Rs6864584	CC	2 (0.002)	5 (0.004)	0.50	0.706	NS	0.559 (0.11 to 2.89)
	CT	64 (0.079)	105 (0.093)	1.11	0.327	NS	0.84 (0.61 to 1.16)
	TT	743 (0.918)	1022 (0.903)	1.39	0.262	NS	1.21 (0.88 to 1.67)
	C	68 (0.042)	115 (0.051)	1.61	0.204	NS	0.82 (0.60 to 1.11)
	T	1550 (0.958)	2149 (0.949)	1.61	0.204	NS	1.22 (0.90 to 1.66)
Rs1128334	AA	128 (0.158)	137 (0.121)	5.54	0.022	NS	1.37 (1.05 to 1.77)
	AG	366 (0.452)	510 (0.451)	0.01	0.963	NS	1.01 (0.84 to 1.21)
	GG	315 (0.389)	485 (0.428)	2.97	0.092	NS	0.85 (0.71 to 1.02)
	A	622 (0.384)	784 (0.346)	5.94	0.015	NS	1.18 (1.03 to 1.35)
	G	996 (0.616)	1480 (0.654)	5.94	0.015	NS	0.85 (0.74 to 0.97)
Rs10893872	CC	275 (0.340)	335 (0.296)	4.24	0.042	NS	1.23 (1.01 to 1.49)
	CT	393 (0.486)	583 (0.515)	1.61	0.214	NS	0.89 (0.74 to 1.07)
	TT	141 (0.174)	214 (0.189)	0.69	0.439	NS	0.91 (0.72 to 1.15)
	C	943 (0.583)	1253 (0.553)	3.31	0.069	NS	1.13 (0.99 to 1.28)
	T	675 (0.417)	1011 (0.447)	3.31	0.069	NS	0.88 (0.78 to 1.01)

p_c^a , Bonferroni corrected and gender adjusted p value.

p_c , Bonferroni corrected p value.

BD, Behçet's disease; NS, not significant; SNP, single nucleotide polymorphism.

Table 3 Frequencies of genotypes and alleles of micro RNA (miR)-146a and Ets-1 polymorphism in patients with VKH and controls

SNPs	Genotype/allele	VKH (N=613)	Control (N=1132)	χ^2	p Value	p _c Value	OR (95% CI)
Rs2910164	GG	64 (0.104)	154 (0.136)	3.64	0.058	NS	0.74 (0.54 to 1.01)
	GC	273 (0.445)	518 (0.458)	0.24	0.65	NS	0.95 (0.78 to 1.16)
	CC	276 (0.450)	460 (0.406)	3.14	0.08	NS	1.20 (0.98 to 1.46)
	G	399 (0.325)	826 (0.365)	4.97	0.03	NS	1.18 (1.02 to 1.37)
	C	827 (0.675)	1438 (0.635)	4.97	0.03	NS	0.85 (0.73 to 0.98)
Rs57095329	AA	448 (0.731)	761 (0.672)	6.41	0.012	NS	1.32 (1.07 to 1.61)
	AG	152 (0.248)	342 (0.302)	5.75	0.017	NS	0.76 (0.61 to 0.95)
	GG	13 (0.021)	29 (0.026)	0.33	0.626	NS	0.82 (0.43 to 1.60)
	A	1048 (0.855)	1864 (0.823)	5.71	0.017	NS	1.26 (1.04 to 1.53)
	G	178 (0.145)	400 (0.177)	5.71	0.017	NS	0.79 (0.65 to 0.96)
Rs6864584	CC	1 (0.002)	5 (0.004)	0.901	0.672	NS	0.368 (0.04 to 3.16)
	CT	42 (0.069)	105 (0.093)	3.03	0.087	NS	0.719 (0.50 to 1.04)
	TT	570 (0.93)	1022 (0.903)	0.087	0.062	NS	1.427 (0.99 to 2.06)
	C	44 (0.036)	115 (0.051)	4.06	0.043	NS	0.70 (0.49 to 0.99)
	T	1182 (0.964)	2149 (0.949)	4.06	0.043	NS	1.44 (1.01 to 2.05)
Rs1128334	AA	97 (0.158)	137 (0.121)	4.73	0.033	NS	1.36 (1.03 to 1.81)
Rs10893872	AG	264 (0.431)	510 (0.451)	0.64	0.45	NS	0.92 (0.76 to 1.13)
	GG	252 (0.411)	485 (0.428)	0.49	0.51	NS	0.93 (0.76 to 1.14)
	A	458 (0.374)	784 (0.346)	2.58	0.11	NS	1.13 (0.97 to 1.30)
	G	768 (0.626)	1480 (0.654)	2.58	0.11	NS	0.89 (0.77 to 1.03)
	CC	157 (0.256)	335 (0.296)	3.14	0.08	NS	0.82 (0.66 to 1.02)
	CT	329 (0.537)	583 (0.515)	0.75	0.39	NS	1.09 (0.89 to 1.33)
	TT	127 (0.207)	214 (0.189)	0.83	0.38	NS	1.12 (0.87 to 1.43)
	C	618 (0.530)	666 (0.544)	2.69	0.10	NS	0.89 (0.77 to 1.02)
	T	548 (0.470)	558 (0.456)	2.69	0.10	NS	1.12 (0.97 to 1.29)

p_c, Bonferroni corrected and gender adjusted p value.p_c, Bonferroni corrected p value.

NS, not significant; SNP, single nucleotide polymorphism; VKH, Vogt-Koyanagi-Harada.

compared to the GG (25.53 ± 4.82 ng/ml, $p=0.001$) and GC cases (23.01 ± 5.17 ng/ml, $p<0.001$), respectively (figure 2).

DISCUSSION

In the present study, we investigated the association of five SNPs of hsa-miR-146a and the transcription factor Ets-1 with BD and VKH in a Chinese Han population. The results showed that individuals carrying the CC genotype of miR-146a rs2910164

had a lower risk of developing BD. Individuals having the CC genotype of rs2910164 showed a lower miR-146a expression as compared to rs2910164 GG individuals and a lower expression of IL-17, TNF α and IL-1 β . We failed to show any association of the tested five SNPs of *miR-146a* and *Ets-1* gene with VKH disease.

The choice of SNPs of these two genes as candidates was principally based on earlier studies.^{19 22–24} A total of 12 variants of the miR-146a gene were identified by Luo *et al.*¹³ Of the 12, 9 were already reported in the dbSNP database Build 130. Five of these nine variants (rs2910164, rs73318382, rs57095329, rs6864584 and rs17057381) had a minor allele frequency of $>1\%$ and the other four variants were monozygous. SNPs rs57095329 and rs73318382 are in strong linkage disequilibrium (LD; $r^2=0.81$) with each other and the former has been shown to be highly associated with SLE in a Chinese Han population,¹³ and was therefore included in our study. With regard to SNP rs17057381, only one GG genotype has been reported in a representative Asian population (Han Chinese in Beijing, CHB) (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=17057381), although the frequency of C allele was reported to be 0.016 in another Chinese population.¹³ A total of 900 individuals (300 normal controls, 300 patients with BD and 300 patients with VKH) was therefore tested to examine whether there were variants in this SNP rs17057381. Our result only showed the GG genotype in this population (data not shown), which is consistent with the HapMap database and therefore this SNP was not included in this study. As Ets-1 may strongly affect miR-146a promoter activity and directly regulate miR-146a expression,^{16 17} we also examined whether its variants influence the susceptibility to BD. Five SNPs of *Ets-1* gene were investigated with SLE, and only rs1128334 and rs10893872, which located in the 3'-UTR of the this gene, were identified to be linked with this disease. As SLE and BD may




Figure 1 Micro RNA (miR)-146a expression with three different genotypes of single nucleotide polymorphism (SNP) rs2910164 in peripheral blood mononuclear cells (PBMCs). TaqMan real-time PCR analysis of mature miR-146a expression in PBMCs derived from healthy individuals of SNP rs2910164 GG, GC and CC genotypes ($n=8$ per group). The y axis represents relative mature miR-146a expression level by real-time PCR of each genotype of SNP rs2910164. Data are shown as mean \pm SD. * $p<0.05$; ** $p<0.01$.




Figure 2 Cytokine production with three different genotypes of single nucleotide polymorphism (SNP) rs2910164 in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-17, tumour necrosis factor (TNF) α , IL-1 β , IL-8, IL-6 and monocyte chemoattractant protein (MCP)-1 in supernatants of PBMCs derived from healthy individuals of SNP rs2910164 CC (n=25–26), GC (n=31–34) and GG (n=22–23) genotypes were measured by ELISA. The horizontal line indicates the mean expression level within each group. *p<0.05; **p<0.01.

share a gene background in common,^{25–29} we therefore included these two SNPs in this study.

To the best of our knowledge, the possible association of *miR-146a* and *Ets-1* gene polymorphisms with BD and VKH disease have not yet been reported. This is the first study to identify an association of SNP rs2910164 of *miR-146a* with autoinflammatory disease. Our study showed a significantly decreased frequency of the CC genotype and C allele of this SNP in patients with BD, suggesting that this miR may be a susceptibility factor to this disease. A similar association has been reported in papillary thyroid carcinoma in European Caucasians²² and oesophageal squamous cell carcinoma in Chinese Han.³⁰ These results suggest that the rs2910164 CC genotype and C allele are common predisposing factors for these diseases despite the fact that the pathogenic mechanisms underlying cancer and BD are totally different.

The aforementioned results identified a strong association between rs2910164 in the pre-*miR-146a* gene with BD. A further study was designed to investigate whether this SNP influenced *miR-146a* expression and the production of

cytokines importantly involved in BD development. The disease group is not homogenous due the influence of various proinflammatory processes and the fact that the patients are treated with immunosuppressive drugs. We expect that these factors would influence gene expression and cytokine production and we therefore only investigated the *miR-146a* expression and cytokine production in healthy individuals with different genotypes of SNP rs2910164 in the *miR-146a* gene. Our study showed that the rs2910164 GG genotype could upregulate mature *miR-146a* expression. This finding is consistent with findings reported in papillary thyroid carcinoma in European Caucasians.²² The results also revealed that the IL-17, TNF α and IL-1 β levels from individuals carrying the rs2910164 CC genotype were significantly decreased as compared to the other two genotypes. The lower IL-17, TNF α and IL-1 β response in the CC genotype would fit in with the protection against disease in the patients with this genotype. It is worthwhile to point out that there was a somewhat high variation in the release of the tested cytokines by PBMCs stimulated with LPS. This is probably due to the fact that other genes may also play a

role in cytokine expression. A recent in vitro study showed that miR-146a was involved in LPS-induced cross-tolerance in a human macrophage cell line and showed that miR-146a operated as a negative regulatory feedback mechanism to prevent an inflammatory reaction.³¹ These data are not in agreement with our study, where we observed protection against BD with a genotype associated with lower miR-146a expression. The reasons for this discrepancy are unclear but could be due to the use of different types of cells (macrophage cell lines versus freshly isolated PBMCs). Our results are, by and large, consistent with those reported in patients with rheumatoid arthritis, in which upregulated miR-146a expression was found to be associated with increased IL-17 expression in PBMCs.^{32–33} The findings presented here are also not in agreement with earlier studies in mice where miR-146a was shown to act as a negative regulator possibly via negative regulation of the Toll-like receptor (TLR) signalling pathway by targeting TNF receptor associated factor (TRAF)6³⁴ and via increasing forkhead box P3 (FoxP3) expression in regulatory cells.³⁵ Although the reasons for these controversies are not clear, differences between humans and mice might be one of the explanations. It is worthwhile to point out that a dose–response relationship was only noted in IL-17 and TNF α expression, but not present in IL-1 β expression. The reasons as to why there is no dose–response relationship in IL-1 β expression need to be clarified in future studies. Unexpectedly, we found an increased production of IL-8 in the CC genotype, which seems to be paradoxical to the results for IL-17, TNF α and IL-1 β expression. A similar result was also reported in a study on ulcerative colitis in which the expression of IL-8 was inconsistent with that of IL-17 and IL-1 β .³⁶ Collectively, these results suggest that this SNP functionally affects the miR-146a expression level and also influences proinflammatory cytokine production.

Contrary to the result in patients with BD, we did not observe an association of these five SNPs with susceptibility to VKH. The discrepancy in the association of miR-146a polymorphisms between BD and VKH disease disclosed in the present study may be partially due to the fact that these two uveitis entities are mediated by different immunological and inflammatory pathways. BD, for instance, is now seen as an autoinflammatory disease, whereas VKH is considered an autoimmune disease directed against melanocytes.^{1–37}

There are a number of limitations to our study. Our study identified an association of miR-146a polymorphisms with BD in a predominantly male^{38–39} Han Chinese population. Although this result was from gender adjustment, it should be validated in a gender-matched population. As replication in an independent set of samples is an important requirement for all association studies, the association of SNP rs2910164 in the miR-146 gene with BD needs further confirmation. BD involves multiple organs and our patients, recruited from a department of ophthalmology, all had uveitis and may therefore represent a subpopulation of this disease. The susceptible SNP identified in our study may only be associated with uveitis in BD and further studies are needed to investigate the association of miR-146a with BD in patients from other medical departments, such as stomatology and dermatology. In addition, although we failed to find any association of SNP rs57095329, rs6864584, rs1128334, rs10893872 with BD and VKH disease, our study does not rule out the possibility that other SNPs of Ets-1 are associated with both diseases. Further studies are needed to clarify this issue.

In conclusion, our study identified a strong association of rs2910164 in the pre-miR-146a gene with BD. Furthermore,

our study suggested that it may affect the genetic predisposition to this disease possibly through modulating expression of mature miR-146a and influencing the control of proinflammatory cytokine production.

Acknowledgements The authors would like to thank all donors enrolled in the present study.

Contributors QZ designed and performed the experiment, performed data analysis and wrote the manuscript. SH was involved in data analysis and writing of the manuscript. PY designed the experiment and was involved in writing the manuscript. All of the authors have given permission to be named.

Funding This work was supported by Natural Science Foundation Major International (Regional) Joint Research Project (30910103912), National Basic Research Program of China (973 Program) (2011CB510200), Key Project of Natural Science Foundation (81130019), National Natural Science Foundation Project (30973242), Research Fund for the Doctoral Program of Higher Education of China (20115503110002), Chongqing Key Laboratory of Ophthalmology (CSTC, 2008CA5003), Key Project of Health Bureau of Chongqing (2012-1-003), Key Project of Health Bureau of Chongqing (2012-1-003) and Fund for PAR-EU Scholars Program.

Competing interests None.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of the Ethical Committee of Chongqing Medical University.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 Direskeneli H. Autoimmunity vs autoinflammation in Behçet's disease: do we oversimplify a complex disorder? *Rheumatology (Oxford)* 2006;45:1461–5.
- 2 Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. *N Engl J Med* 1999;341:1284–91.
- 3 Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. *Surv Ophthalmol* 1995;39:265–92.
- 4 Murakami S, Inaba Y, Mochizuki M, et al. A nation-wide survey on the occurrence of Vogt-Koyanagi-Harada disease in Japan. *Nihon Ganka Gakkai Zasshi* 1994;98:389–92.
- 5 Ishikawa A, Shiono T, Uchida S. Vogt-Koyanagi-Harada disease in identical twins. *Retina* 1994;14:435–7.
- 6 Rutzen AR, Ortega-Larrocea G, Schwab IR, et al. Simultaneous onset of Vogt-Koyanagi-Harada syndrome in monozygotic twins. *Am J Ophthalmol* 1995;119:239–40.
- 7 Fresko I, Soy M, Hamuryudan V, et al. Genetic anticipation in Behçet's syndrome. *Ann Rheum Dis* 1998;57:45–8.
- 8 Verity DH, Marr JE, Ohno S, et al. Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. *Tissue Antigens* 1999;54:213–20.
- 9 Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. *Nat Genet* 2010;42:698–702.
- 10 Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. *Nat Genet* 2010;42:703–6.
- 11 Zhao M, Jiang Y, Abrahams IW. Association of HLA antigens with Vogt-Koyanagi-Harada syndrome in a Han Chinese population. *Arch Ophthalmol* 1991;109:368–70.
- 12 Shu Q, Yang P, Hou S, et al. Interleukin-17 gene polymorphism is associated with Vogt-Koyanagi-Harada syndrome but not with Behçet's disease in a Chinese Han population. *Hum Immunol* 2010;71:988–91.
- 13 Luo X, Yang W, Ye DQ, et al. A functional variant in MicroRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. *PLoS Genet* 2011;7:e1002128.
- 14 Liu Z, Xiao B, Tang B, et al. Up-regulated microRNA-146a negatively modulate Helicobacter pylori-induced inflammatory response in human gastric epithelial cells. *Microbes Infect* 2010;12:854–63.
- 15 Tang Y, Luo X, Cui H, et al. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. *Arthritis Rheum* 2009;60:1065–75.
- 16 Yu Z, Li Z, Jolicœur N, et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. *Nucleic Acids Res* 2007;35:4535–41.
- 17 Clop A, Marcq F, Takeda H, et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. *Nat Genet* 2006;38:813–18.
- 18 Okuducu AF, Zils U, Michaelis SA, et al. Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade

Clinical and epidemiological research

- 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. *Cancer* 2006;107:1365–72.
- 19 Yang W, Shen N, Ye DQ, *et al.* Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. *PLoS Genet* 2010;6:e1000841.
 - 20 Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's disease. *Lancet* 1990;335:1078–80.
 - 21 Read RW, Holland GN, Rao NA, *et al.* Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. *Am J Ophthalmol* 2001;131:647–52.
 - 22 Jazdzewski K, Murray EL, Franssila KJ, *et al.* Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. *Proc Natl Acad Sci USA* 2008;105:7269–74.
 - 23 Xu T, Zhu Y, Wei QK, *et al.* A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. *Carcinogenesis* 2008;29:2126–31.
 - 24 Yang B, Zhang JL, Shi YY, *et al.* Association study of single nucleotide polymorphisms in pre-miRNA and rheumatoid arthritis in a Han Chinese population. *Mol Biol Rep* 2011;38:4913–9.
 - 25 Namjou B, Sestak AL, Armstrong DL, *et al.* High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. *Arthritis Rheum* 2009;60:1085–95.
 - 26 Hou S, Yang Z, Du L, *et al.* Genome-wide association study identifies susceptible locus in STAT4 for Behçet's disease in Han Chinese. *Arthritis Rheum* 2012;64:4104–13.
 - 27 Dourmishev L, Kamenarska Z, Hristova M, *et al.* Association of TNF-alpha polymorphisms with adult dermatomyositis and systemic lupus erythematosus in Bulgarian patients. *Int J Dermatol* 2012;51:1467–73.
 - 28 Kamoun M, Chelbi H, Houman MH, *et al.* Tumor necrosis factor gene polymorphisms in Tunisian patients with Behçet's disease. *Hum Immunol* 2007;68:201–5.
 - 29 Wang JJ, Jiang LQ, He B, *et al.* The association of CTLA-4 and CD28 gene polymorphisms with idiopathic ischemic stroke in the paediatric population. *Int J Immunogenet* 2009;36:113–18.
 - 30 Guo H, Wang K, Xiong G, *et al.* A functional variant in microRNA-146a is associated with risk of esophageal squamous cell carcinoma in Chinese Han. *Fam Cancer* 2010;9:599–603.
 - 31 Nahid MA, Satoh M, Chan EK. Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. *J Immunol* 2011;186:1723–34.
 - 32 Pauley KM, Satoh M, Chan AL, *et al.* Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. *Arthritis Res Ther* 2008;10:R101.
 - 33 Niimoto T, Nakasa T, Ishikawa M, *et al.* MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. *BMC Musculoskelet Disord* 2010;11:209.
 - 34 Hou J, Wang P, Lin L, *et al.* MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. *J Immunol* 2009;183:2150–8.
 - 35 Lu LF, Boldin MP, Chaudhry A, *et al.* Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. *Cell* 2010;142:914–29.
 - 36 Rodriguez-Perlvarez ML, Garcia-Sanchez V, Villar-Pastor CM, *et al.* Role of serum cytokine profile in ulcerative colitis assessment. *Inflamm Bowel Dis* 2012;18:1864–71.
 - 37 Gul A. Behçet's disease as an autoinflammatory disorder. *Curr Drug Targets Inflamm Allergy* 2005;4:81–3.
 - 38 Yang P, Fang W, Meng Q, *et al.* Clinical features of chinese patients with Behçet's disease. *Ophthalmology* 2008;115:312–8 e314.
 - 39 Jiang Z, Yang P, Hou S, *et al.* IL-23R gene confers susceptibility to Behçet's disease in a Chinese Han population. *Ann Rheum Dis* 2010;69:1325–8.



***MicroRNA-146a* and *Ets-1* gene polymorphisms in ocular Behçet's disease and Vogt–Koyanagi–Harada syndrome**

Qingyun Zhou, Shengping Hou, Liang Liang, et al.

Ann Rheum Dis 2014 73: 170-176 originally published online December 25, 2012

doi: 10.1136/annrheumdis-2012-201627

Updated information and services can be found at:

<http://ard.bmj.com/content/73/1/170.full.html>

These include:

Data Supplement

"Supplementary Data"

<http://ard.bmj.com/content/suppl/2012/12/21/annrheumdis-2012-201627.DC1.html>

References

This article cites 39 articles, 8 of which can be accessed free at:

<http://ard.bmj.com/content/73/1/170.full.html#ref-list-1>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Immunology \(including allergy\)](#) (4199 articles)

[Ophthalmology](#) (109 articles)

[Genetics](#) (796 articles)

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>